Letters POPADAD trial

Time for a proper study of aspirin after a vascular event?

BMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a2583 (Published 19 November 2008) Cite this as: BMJ 2008;337:a2583
  1. John G F Cleland, professor of cardiology1
  1. 1Castle Hill Hospital, University of Hull, Kingston upon Hull HU16 5JQ
  1. j.g.cleland{at}hull.ac.uk

    Belch et al add to the documentation that long term aspirin has little or no benefit in patients who have or are at risk of atherosclerotic cardiovascular disease.1 2

    Few long term trials of aspirin have shown a reduction in mortality or major morbidity. However, editors of journals persist in publishing papers on aspirin with conclusions designed to mislead health professionals and the public.

    The New …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription